House Dust Mite Allergy Market Report Provides Insights Into Market Evolution And Growth Prospects

The house dust mite allergy market is gearing up for significant expansion as new treatment options and growing awareness drive demand. With advancements in personalized therapies and broader acceptance of home-based care, the industry is set to transform how patients manage and prevent allergic reactions caused by house dust mites. Let's explore the market's expected growth, key players, emerging trends, and segmentation to understand its future landscape.

Expected Market Growth and Valuation of the House Dust Mite Allergy Market
The house dust mite allergy market is projected to experience rapid growth, reaching a valuation of $4.62 billion by 2030. This represents a compound annual growth rate (CAGR) of 14.3%. Several factors contribute to this expansion, including the increased use of personalized immunotherapy, a stronger focus on preventive allergy care, and the rise of home-based allergy management solutions. Additionally, the demand for long-term symptom control is growing, supported by advances in biologic allergy treatments. Key market trends over the forecast period include wider adoption of immunotherapy, increased use of sublingual allergy tablets, early diagnostic testing becoming more common, and a stronger emphasis on customized allergy treatments.

Download a free sample of the house dust mite allergy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9304&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Key Players Leading the House Dust Mite Allergy Market
The market features a number of prominent companies driving innovation and market penetration. These include Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, and GlaxoSmithKline.

A notable collaboration took place in September 2025 when France-based Stallergenes Greer partnered with Nuance Pharma to expand the distribution of its house-dust-mite sublingual immunotherapy tablet, Actair, in China. This partnership aims to improve patient access to scientifically supported allergy treatments and enhance the availability of advanced immunotherapy options for individuals suffering from house dust mite-induced allergic rhinitis. Nuance Pharma specializes in respiratory, immunology, and specialty-care therapeutics within the Chinese market.

View the full house dust mite allergy market report:
https://www.thebusinessresearchcompany.com/report/house-dust-mite-allergy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Emerging Trends and Innovations Shaping the House Dust Mite Allergy Market
Companies are increasingly focusing on developing novel treatment methods, particularly sublingual tablets, to address the rising prevalence of house dust mite allergies. Sublingual tablets work by delivering small doses of allergens under the tongue, helping patients build tolerance over time. For example, in January 2023, Denmark-based ALK-Abelló A/S gained FDA approval for ODACTRA, a sublingual tablet intended for adolescents aged 12 to 17, extending its earlier use for adults. Nearly half of all allergy sufferers are sensitive to house dust mites, making this treatment especially significant. Clinical trials demonstrated that ODACTRA effectively reduced allergy symptoms and had a safety profile comparable to adult patients. However, because of possible severe allergic reactions, patients are advised to keep auto-injectable epinephrine available.

Segments Covered in the House Dust Mite Allergy Market Report
The house dust mite allergy market is analyzed through several key segments, providing a detailed view of the industry:
1) Product Type: Tablets, Nasal Drops, Injectable
2) Diagnosis Method: Skin Prick Test (SPT), Specific Immunoglobulin E (IgE) Blood Test, Other Diagnosis Methods
3) Dosage Forms: Solid, Liquid
4) End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Further breakdowns include:
- Tablets: Sublingual Tablets, Oral Tablets
- Nasal Drops: Antihistamine Nasal Drops, Corticosteroid Nasal Drops
- Injectable Treatments: Allergen Immunotherapy Injections, Corticosteroid Injections

This comprehensive segmentation helps stakeholders identify opportunities and challenges within each category, supporting strategic decision-making in the evolving house dust mite allergy market.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.